Company / R&D Expense
RECURSION PHARMACEUTICALS, INC. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$475.3M
FY2025
5-year range
$63.3M / $475.3M
FY2021-FY2025
Trend
+51.2%
vs FY2024
Sector context
#35 of 210
Health Care
What the data says
RECURSION PHARMACEUTICALS, INC.'s r&d expense of $475M is higher than 83% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $63M in FY2022 to $475M in FY2025.
Based on SEC 10-K filings.
$475M in FY2025 with a 5-year CAGR of +49.7%. Top quartile in the Health Care sector.
Improved from $241M to $475M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +95.8%
- 5-Year CAGR
- +49.7%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 210This company $475.3M Sector average $644.0M
▼
-26.2% below sector average
Key checks
Key Insights
- RECURSION PHARMACEUTICALS, INC.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +49.7%, indicating consistent growth.
- In FY2025, r&d expense increased 51.2% year-over-year.
- Ranks #35 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $475.3M | +51.2% |
| FY2024 | $314.4M | +30.3% |
| FY2023 | $241.2M | +281.0% |
| FY2022 | $63.3M | -53.2% |
| FY2021 | $135.3M | +113.6% |
| FY2020 | $63.3M | +38.2% |
| FY2019 | $45.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026